Related Experiment Videos
Alterations in signal transducing molecule CD3 zeta in patients with neoplastic diseases
I Frydecka1, P Kaczmarek, D Boćko
1Department of Hematology, University Medical School, Pasteura, Wrocław, Poland.
Abstract:
The impairment of immune cell functions in cancer patients may result from impairment of signal transduction. Recent studies have demonstrated altered expression and function of signal transduction molecule CD3 zeta in T and natural killer cells in patients with neoplastic diseases. Tumor infiltrating lymphocytes are more affected than peripheral blood lymphocytes. CD3 zeta expression is more prominent in advanced stage of the disease and correlates with reduced proliferative response, IFN-gamma, IL-2, TNF-alpha production.
Insights
Immune cell dysfunction in cancer patients is linked to impaired signal transduction. CD3 zeta molecule alterations in T and NK cells correlate with advanced cancer stages and reduced immune responses.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- Immune cell dysfunction is a hallmark of cancer, potentially stemming from impaired signal transduction pathways.
- The CD3 zeta (CD3Z) signaling molecule plays a critical role in T cell and natural killer (NK) cell activation.
- Previous research suggests altered CD3 zeta expression and function in cancer patients.
Purpose of the Study:
- To investigate the expression and function of the CD3 zeta signaling molecule in immune cells of cancer patients.
- To determine if CD3 zeta alterations correlate with cancer stage and immune cell activity.
Main Methods:
- Analysis of CD3 zeta expression in T lymphocytes and NK cells from cancer patients.
- Comparison of immune cells from tumor infiltrates versus peripheral blood.
- Assessment of immune cell function, including proliferative response and cytokine production (IFN-gamma, IL-2, TNF-alpha).
Main Results:
- CD3 zeta expression and function are altered in T and NK cells of cancer patients.
- Tumor-infiltrating lymphocytes exhibit more significant CD3 zeta impairment compared to peripheral blood lymphocytes.
- Reduced CD3 zeta expression correlates with advanced disease stage.
- Lower CD3 zeta levels are associated with diminished proliferative capacity and reduced production of key cytokines like IFN-gamma, IL-2, and TNF-alpha.
Conclusions:
- Impaired CD3 zeta signaling contributes to immune cell dysfunction in cancer.
- CD3 zeta alterations are more pronounced in advanced cancer and are linked to reduced anti-tumor immune responses.
- Targeting CD3 zeta pathways may offer therapeutic potential in oncology.